Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year

Phase 2

Terminated

Conditions: Psychotic Disorders

Interventions: Drug: BI 409306
Drug: Placebo

First Posted Date: 2017-07-26

Last Posted Date: 2022-06-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 50

Registration Number: NCT03230097

Locations: 🇺🇸
Michigan Clinical Research Institute PC, Ann Arbor, Michigan, United States
🇺🇸
Precise Research Centers, Flowood, Mississippi, United States
🇺🇸
PRIME Clinic, New Haven, Connecticut, United States

and more 30 locations

The VOLTAIRE-X Trial Looks at the Effect of Switching Between Humira® and BI 695501 in Patients With Plaque Psoriasis

Phase 3

Completed

Conditions: Psoriasis

Interventions: Drug: BI 695501
Drug: Humira®

First Posted Date: 2017-07-06

Last Posted Date: 2021-07-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 259

Registration Number: NCT03210259

Locations: 🇺🇸
Universal Clinical Research, Hialeah, Florida, United States
🇺🇸
Kansas City Dermatology, PA, Overland Park, Kansas, United States
🇺🇸
MediSearch Clinical Trials, Saint Joseph, Missouri, United States

and more 46 locations

This Study in Healthy Men Tests How Different Doses of BI 1358894 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Looks at How Food Influences the Amount of BI 1358894 in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1358894 (Test)
Drug: Placebo
Drug: BI 1358894
Drug: BI 1358894 (Reference)

First Posted Date: 2017-07-06

Last Posted Date: 2019-02-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 83

Registration Number: NCT03210272

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

Comparison of the Medication Adherence of Patients Treated With Telmisartan/Hydrochlorothiazide or Telmisartan/Amlodipine Fixed Dose Combination (FDC) Versus Double-pill Combination Therapy in Real-world Japanese Therapeutic Practice

Withdrawn

Conditions: Hypertension

Interventions: Drug: subjects treated with telmisartan/hydrochlorothiazide
Drug: Subjects treated with Telmisartan and amlodipine
Drug: subjects treated with Telmisartan+hydrochlorothiazide double-pill combination group
Drug: subjects treated with telmisartan+amlodipine double pill

First Posted Date: 2017-07-02

Last Posted Date: 2022-06-28

Lead Sponsor: Boehringer Ingelheim

Registration Number: NCT03205137

Locations: 🇯🇵
Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan

This Study is Done in Healthy Chinese and Japanese Volunteers; it Looks at How BI 690517 is Taken up in the Body and How Well it is Tolerated

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 690517
Drug: Placebo

First Posted Date: 2017-07-02

Last Posted Date: 2018-01-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 56

Registration Number: NCT03206632

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

Evaluation of Safety and Tolerability of Single Rising Doses of BI 473494 in Healthy Subjects

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: Placebo
Drug: BI 473494

First Posted Date: 2017-06-22

Last Posted Date: 2022-07-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT03195088

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

This Study Tests in Healthy Korean Women Which Effects BI 409306 and a Birth-control Pill Have on Each Other

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Microgynon® 30
Drug: BI 409306

First Posted Date: 2017-06-20

Last Posted Date: 2024-03-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT03193307

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

Specific Use-Result of Spiriva Respimat® in Asthmatics

Completed

Conditions: Asthma

Interventions: Drug: Spiriva Respimat

First Posted Date: 2017-06-15

Last Posted Date: 2019-11-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 193

Registration Number: NCT03188120

Locations: 🇯🇵
Nippon Boehringer Ingelheim Co., Ltd, Tokyo, Japan

Patients' Assessment of Satisfaction for Stroke Prevention in Atrial Fibrillation

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Pradaxa®

First Posted Date: 2017-06-14

Last Posted Date: 2020-02-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1315

Registration Number: NCT03187197

Locations: 🇨🇳
China Medical University Hospital, Taichung, Taiwan
🇨🇳
Mackay Memorial Hospital, Taipei, Taiwan
🇨🇳
Show Chwan Memorial Hospital, Changhua, Taiwan

and more 21 locations

Japanese Pradaxa PMS, Long Term

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Prazaxa® Capsules

First Posted Date: 2017-06-05

Last Posted Date: 2022-04-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 5660

Registration Number: NCT03175198

Locations: 🇯🇵
Nippon Boehringer Ingelheim Co., Ltd, Tokyo, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy